anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adolescent idiopathic scoliosis (AIS) is a three-dimensional structural deformity of the spine that affects 2-3% of adolescents under the age of 16. AIS etiopathogenesis is not completely understood; however, the disease phenotype is correlated to multiple genetic loci and results from genetic-environmental interactions. One of the primary, still unresolved issues is the implementation of reliable diagnostic and prognostic markers. For clinical management improvement, predictors of curve progression are particularly needed. Recently, an epigenetic contribution to AIS development and progression was proposed; nevertheless, validation of data obtained in peripheral tissues and identification of the specific mechanisms and genes under epigenetic control remain limited. In this study, we propose a methodological approach for the identification of epigenetic markers of AIS progression through an original workflow based on the preliminary characterization of local expression of candidate genes in tissues directly involved in the pathology. The feasibility of the proposed methodological protocol has been originally tested here in terms of identification of the putative epigenetic markers of AIS progression, collection of the different tissues, retrieval of an appropriate amount and quality of RNA and DNA, and identification of suitable reference genes.
PURPOSE: To obtain a pigment for a coating material, etc., by coating a synthetic mica having a smooth particle surface and an iron content equal to or lower than a specific value with a metal oxide, showing no yellow at a mass tone angle and a shade part, causing no faded color of an interference color. CONSTITUTION: A synthetic mica (e.g. tetrasilicon fluoride mica, etc.) containing Ti, Zn, Na, B, Li, Ca, Ge, Sr, Zr, etc., having <=1.58 average refractive index and <=1.0% iron content is mixed with water while stirring, blended with a solution of titanyl sulfate, rapidly heated to 100 deg.C, reacted at the temperature for 3 hours, filtered, washed with water and dried at 110 deg.C to give powder,, which is baked at 800 deg.C for 1 hour to give the objective pigment for a coating material, etc., by coating a synthetic mica which comprises the synthetic mica coated with a metal oxide (e.g. titanium dioxide, etc.), shows no yellow at a mass tone angle and a shade part, has solved the problem of a faded color of an interference color and is useful as a coating composition, cosmetic, ink, plastics etc.
PURPOSE:Dried stable pharmaceutical preparation of urokinase useful as a remedy for vascular embolic disease, obtained by blending dried urokinase with a basic amino acid as a stabilizer. CONSTITUTION:Dried urokinase is blended with at least one basic urokinase (e.g., arginine, lysine, histidine, etc.) as a stabilizer, to give stable pharmaceutical preparation of urokinase. Urokinase which is unstable in any state, e.g., in urine, in a neutral solvent during purification process, or in (lyophilized) dried pharmaceutical preparation can be stabilized by adding the basic amino acid to it. In blending ratio, 10,000-1,000,000IU urokinase is blended with 10-50mg amino acid. The stabilizer of this invention can prevent decomposition of urokinase by lyophilization, so preferably it is added to urokinase before lyophilization.
This study assessed the effectiveness of a program aimed at improving the early numeracy skills of students with moderate intellectual disability. The persistence of the acquired skills and the program's impact on learning were monitored. Feedback from the students and their mothers was also gathered. Using a multiple-probe design across subjects, the results were visually presented through graphical analysis. Three male students aged 8-9 years participated. After obtaining high-reliability findings from reliability analyses, results showed the program effectively increased students' number skills with a high effect size. These skills persisted post-intervention, and both students and mothers expressed positive views of the intervention.
The study will comprise of three groups based on hepatic function. Participants will be screened for up to 28 days prior to investigational product (IP) administration on Day 1. Eligible participants will be admitted to the clinical unit on Day -1 and will be residential for a single period of six days/five nights. On Day 1, participants will receive a single oral dose of fezolinetant under fasting conditions followed by a 96-hour in-house blood and urine sampling period. Participants are to remain semirecumbent for four hours postdose. Standard safety and tolerability assessments will be conducted. Participants will be discharged from the clinical unit on Day 5 on the condition that all required assessments have been performed and that there are no medical reasons for a longer stay in the clinical unit.

The study will be completed with an end-of-study visit (ESV). The ESV will take place five to nine days after the last pharmacokinetic sample is collected or at the time of early discontinuation from the study.
PURPOSE:To provide the title composition useful for the prevention or therapy of periodontitis, containing blood antibody or milk antibody prepared by immunizing a mammal with Treponema denticola film as antigen. CONSTITUTION:The objective composition containing blood antibody or milk antibody prepared by immunizing a mammal with Treponema denticola film, esp. the protein present on its surface layer as antigen, or containing egg antibody prepared by immunizing a bird therewith. Alternatively, the objective composition containing monoclonal antibody produced from hybridoma prepared by cell fusion between (A) antibody productive cells to Treponema denticola film protein antigen and (B) myeloma cells. The amount of said antibody to be contained is such as to be 0.01-10 (pref. 0.01-5)wt.%, and the dose of the present composition to the oral cavity is pref. 0.00001-10g/kg/day in terms of the amount of the antibody.
Compositions comprised of olanzapine and a 5-HT3 receptor antagonist and a polyorthoester polymer are provided to provide extended release of the active agents. Also described are compositions comprising olanzapine and a polyorthoester. The compositions are effective for the prophylactic treatment or treatment of subjects at risk of or suffering from nausea and/or vomiting. The compositions are particularly useful for the prevention or treatment of acute, delayed, breakthrough or refractory chemotherapy induced nausea and vomiting (CINV). The CINV may result from, e.g., highly or moderately emetogenic cancer chemotherapy. The compositions are suitable for delivery via, e.g., intramuscular injection, intradermal injection, and subcutaneous injection.
OBJECTIVES: The specific humoral immune response resulting from inactivated vaccination following by BA.5 infection, and predictors of XBB variants re-infection in BA.5 infection-recovered nasopharyngeal carcinoma (BA.5-RNPC) patients, were explored.
METHODS: Serum SARS-CoV-2 specific antibody levels were assessed using enzyme-linked-immunosorbent-assay. Univariate and multivariate binary logistic regression analyses were conducted to identify factors associated with the magnitude of specific humoral immunity and susceptibility to re-infection by XBB variants.
RESULTS: Our data demonstrates that SARS-CoV-2 specific antibody levels were comparable between BA.5-RNPC patients and BA.5 infection-recovered-non-cancerous (BA.5-RNC) individuals. Specifically, serum levels of anti-ancestral-S1-IgG, anti-ancestral-nucleocapsid-protein (NP)-IgG, anti-BA.5-receptor binding domain (RBD)-IgG and anti-XBB.1.1.6-RBD-IgG were higher in BA.5-RNPC patients compared to those without a prior infection. Compared to BA.5-RNPC patients without vaccination, individuals who received inactivated vaccination exhibited significantly higher levels of anti-ancestral-S1-IgG and anti-XBB.1.16-RBD-IgG. Multivariate logistic regression analysis revealed that inactivated vaccination was the most significant predictor of all tested SARS-CoV-2 specific antibodies response. Subsequent analysis indicated that a low globulin level is an independent risk factor for XBB re-infection in BA.5-RNPC patients.
CONCLUSIONS: The SARS-CoV-2 specific antibodies have been improved in vaccinated BA.5-RNPC patients. However, the baseline immunity status biomarker IgG is an indicators of XBB variant re-infection risk in BA.5-RNPC patients.
The present invention relates to plant essence with equalized fat acids. The present invention contains the following ingredients according to the part by weight: 30.0 to 45.5 parts of ussurian grape oil, 50.0 to 69.5 parts of evening primrose oil and 0.1 to 0.5 part of vitamin E. The present invention contains equalized comprehensive fat acid kinds. The efficiency of a product is strengthened and extended through OPC ingredients. A refining process is not required. The technological content of raw material is high. The ussurian grape oil is used as the raw material, which leads the efficiency to be better.
Gefitinib administered at a dose of 250 mg orally once daily for 12 weeks. PEG-IFNa at 4.0 µg/kg/wk administered subcutaneously once weekly for 6 weeks (cycle repeated once for a total of 2 cycles).
A method of making pyrazinamide comprises protonating pyrazine at either or both of the basic nitrogen atoms in the ring and treating the protonated pyrazine with a reactive amide species to form pyrazinamide. In particular, protonation is carried out with a salt-forming acid, preferably with concentrated sulfuric acid. The amide species may comprise amide radicals and more preferably amide free radicals. The amide species may be derived from an amide precursor in the presence of a free radical generator. The free radical generator may be a two part generator including peroxide and a ferrous salt, in particular hydrogen peroxide and ferrous sulfate. A method of making pyrazinamide may comprise treating pyrazine with salt-forming acid to form a pyrazine salt, admixing the salt with a reactive amide species precursor and treating the mixture with free radical generator precursor to liberate amide free radicals which bond to the pyrazine ring to form pyrazinamide.
Dose-escalation of Pfs25-EPA/Alhydrogel. Participants will receive 1 of 3 doses of Pfs25-EPA/Alhydrogel- 8 micro g, 16 micro g, or 47 micro g.
PURPOSE: Food additive which contains Poria cocos extract is provided to promote growth, prevent and improve osteoporosis. CONSTITUTION: Food additive which promotes growth, prevents and improves osteoporosis comprises crude extract of Poria cocos, soluble extract of polar solvent, or nonpolar solvent soluble extract as active ingredients. Crude extract is soluble to solvent selected from water including purified water, low-grade alcohol of carbon number one to four or the mixture of these. Polar solvent soluble extract is soluble to solvent selected from water, methanol, ethanol, butanol, or the mixed solvent. Non polar soluble extract is soluble to solvent extract selected from hexane, chloroform and ethyl acetate. Food additive includes extract of Poria cocos in weight of 0.1 to 50%.
Patients who have already had a sequencing assay performed to determine the resistance mechanism to a KRAS G12C inhibitor. These patients will be invited to share their data and medical history. Plasma for ctDNA analysis will be optional.
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a prevalent condition that significantly impacts public health. Unfortunately, there are few effective treatment options available. Mendelian randomization (MR) has been utilized to repurpose existing drugs and identify new therapeutic targets. The objective of this study is to identify novel therapeutic targets for COPD.
METHODS: Cis-expression quantitative trait loci (cis-eQTL) were extracted for 4,317 identified druggable genes from genomics and proteomics data of whole blood (eQTLGen) and lung tissue (GTEx Consortium). Genome-wide association studies (GWAS) data for doctor-diagnosed COPD, spirometry-defined COPD (Forced Expiratory Volume in one second [FEV1]/Forced Vital Capacity [FVC] <0.7), and FEV1 were obtained from the cohort of FinnGen, UK Biobank and SpiroMeta consortium. We employed Summary-data-based Mendelian Randomization (SMR), HEIDI test, and colocalization analysis to assess the causal effects of druggable gene expression on COPD and lung function. The reliability of these druggable genes was confirmed by eQTL two-sample MR and protein quantitative trait loci (pQTL) SMR, respectively. The potential effects of druggable genes were assessed through the phenome-wide association study (PheWAS). Information on drug repurposing for COPD was collected from multiple databases.
RESULTS: A total of 31 potential druggable genes associated with doctor-diagnosed COPD, spirometry-defined COPD, and FEV1 were identified through SMR, HEIDI test, and colocalization analysis. Among them, 22 genes (e.g., MMP15, PSMA4, ERBB3, and LMCD1) were further confirmed by eQTL two-sample MR and protein SMR analyses. Gene-level PheWAS revealed that ERBB3 expression might reduce inflammation, while GP9 and MRC2 were associated with other traits. The drugs Montelukast (targeting the MMP15 gene) and MARIZOMIB (targeting the PSMA4 gene) may reduce the risk of spirometry-defined COPD. Additionally, an existing small molecule inhibitor of the APH1A gene has the potential to increase FEV1.
CONCLUSIONS: Our findings identified 22 potential drug targets for COPD and lung function. Prioritizing clinical trials that target these identified druggable genes with existing drugs or novel medications will be beneficial for the development of COPD treatments.
Foreign body (FB) aspiration/ingestion in children represents a major cause of hospital admission and mortality. Evaluating risk factors and identifying trends in specific FB products could improve targeted health literacy and policy changes. A cross-sectional study querying emergency department patients less than 18 years old with a diagnosis of aspirated/ingested FB was conducted using the National Electronic Injury Surveillance System database between 2010 and 2020. Incidence rates per 100 000 people-year were calculated and multivariate analyses were performed to identify risk factors for hospital admission and mortality. There has been a significantly decreasing rate of aspirated (-23.6%; P = .013) but not ingested FB (-9.4%; P = .066) within the study period. Within pediatric aspirated FB, black compared with white patients had decreased odds of same hospital admission (odds ratio [OR]: 0.8), but increased odds of transfer admission (OR: 1.6) and mortality (OR: 9.2) (all, P < .001).
The study will be performed as a 4 week, placebo controlled, pilot trial with a one week run in period. Thirty participants will be randomly assigned to each group for a total enrollment of 60 participants. Participants will be recruited from the Children's' Hospital \& Medical Center's Pediatrician's group. The study coordinators and Investigators will conduct informational lunches at selected pediatrician offices in the Omaha area. The investigators will introduce the topic of the colic study to participants seen for routine follow up who the investigators suspect may meet the diagnostic criteria for colic. The study coordinator will then contact the participants and assess suitability with a brief phone questionnaire. If participants appear to qualify and the participant is agreeable an enrollment appointment will be made to sign the consent, education on the product and how to administer it, teaching regarding diary instrument and completion of the quality of life survey. A brief medical history including the delivery mode and family allergy history will be collected as well as weight and length of the infant at the consent visit. A subset of participants will be asked to provide a stool sample for analysis of calprotectin level (a marker of intestinal inflammation) if the participants are willing to provide this. Participants will administer 5 drops of the study product once a day with a feeding at mid-day. Participants will be instructed to record crying time for a 1 week run in period and then administer the provided drops as directed once a day and record daily crying time on 3 days each week for 4 subsequent weeks. A follow up phone call 2 weeks after starting the product will be conducted to ensure compliance and assess for any adverse events. A final visit after 4 weeks will be conducted for collection of the diary data, completion of the quality of life survey, obtainment of the infant's length and weight and collection of a follow up stool sample if the provided one at baseline.
Audio record the initial visits between patients and their treating physician. Analyze 48 patient-physician dyad recordings using the Roter Interaction Analysis System (RIAS).
When the 750-mg and 1.5-g vials are constituted as directed with Sterile Water for Injection, the solutions of Cefuroxime for Injection for IV administration maintain satisfactory potency for 24 hours at room temperature and for 48 hours under refrigeration (5°C). More dilute solutions, such as 750 mg or 1.5 g plus 100 mL of Sterile Water for Injection, 5% Dextrose Injection, or 0.9% Sodium Chloride Injection, also maintain satisfactory potency for 24 hours at room temperature and 7 days under refrigeration.

These solutions may be further diluted to concentrations of between 1 and 30 mg/mL in the following solutions and will lose not more than 10% activity for 24 hours at room temperature or for at least 7 days under refrigeration: 0.9% Sodium Chloride Injection; 1/6 M Sodium Lactate Injection; Ringer's Injection, USP; Lactated Ringer's Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection; 5% Dextrose Injection; 5% Dextrose and 0.45% Sodium Chloride Injection; 5% Dextrose and 0.225% Sodium Chloride Injection; 10% Dextrose Injection; and 10% Invert Sugar in Water for Injection.

Unused solutions should be discarded after the time periods mentioned above.

Cefuroxime for Injection has also been found compatible for 24 hours at room temperature when admixed in IV infusion with heparin (10 and 50 U/mL) in 0.9% Sodium Chloride Injection and Potassium Chloride (10 and 40 mEq/L) in 0.9% Sodium Chloride Injection. Sodium Bicarbonate Injection USP is not recommended for the dilution of Cefuroxime for Injection.
The present disclosure relates to pregnancy decision support systems and methods. A pregnancy support system is provided for identifying potentially high risk combinations of pregnancy related factors such as symptoms. A classification such as ranking, comparison, or clustering of factors, such as symptoms they may report, provided by a healthcare professional that may be applied to pregnant women is received. A model for identifying potentially high risk combinations of pregnancy related factors is then constructed based on the received factor classifications. Factors for application to the pregnant woman, such as symptoms reported by the pregnant woman, are obtained and applied to the model to determine and support taking of an appropriate course of action. This provides an automated analysis of pregnancy related factors.
To determine the relationships between luteal-phase steroidal hormonal profile and PMS for a large number of women attending a dedicated fertility clinic. This was a retrospective cross-sectional study on women attending a hospital-based clinic for fertility concerns and/or recurrent miscarriage. All participants were assessed with a women's health questionnaire which also included evaluation of premenstrual symptoms. Day of ovulation was identified based on the peak mucus symptom assessed by the woman after instruction in a fertility awareness-based method (FABM). This enabled reliable timing of luteal-phase serum hormone levels to be taken and analysed. Between 2011 and 2021, 894 of the 2666 women undertaking the women's health assessment had at least one evaluable serum luteal hormone test. Serum progesterone levels were up to 10 nmol/L lower for symptomatic women compared with asymptomatic women. This difference was statistically significant (p < 0.05) for the majority of PMS symptoms at ≥ 9 days after the peak mucus symptom. A similar trend was observed for oestradiol but differences were generally not statistically significant. ROC curves demonstrated that steroid levels during the luteal phase were not discriminating in identifying the presence of PMS symptoms. Blood levels for progesterone were lower throughout the luteal phase in women with PMS, with the greatest effect seen late in the luteal phase.
Impaired Liver Function

Do not use WYMZYA Fe in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver [see CONTRAINDICATIONS (4)]. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue WYMZYA Fe if jaundice develops.

Liver Tumors

WYMZYA Fe is contraindicated in women with benign and malignant liver tumors [see CONTRAINDICATIONS (4)]. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) COC users. However, the risk of liver cancers in COC users is less than one case per million users.
The intervention group will send in blood glucoses once a month using the mobile phone app, Diabetes Doctor. All subjects will be evaluated at initial, 3 month, and 6 month visits. They will receive HbA1c on each visit. After 3 months, a Diabetes Quality of Life (QOL) survey will be completed. A Usability and Satisfaction of Diabetes Doctor (USDD) survey will also be obtained. At the 3 month visit, they will also be given the chance to discontinue the mobile app and switch to standard of care. At 6 months, all mobile app users will complete the USDD and satisfaction and QOL survey. If they are not using the mobile app, then they will complete the QOL survey.
Patellofemoral pain is a common condition characterized by pain in anterior knee, around the kneecap. It is known that exercise is beneficial in rehabilitation in general. Exercise programs applied to patients with PFP should include hip and knee-targeted combined exercises. Nowadays, Pilates is used as an effective rehabilitation tool for individuals with musculoskeletal problems, especially in reducing pain and improving function. Therefore, we believe that Pilates exercises can be effective in PFP Considering that PFP is a chronic condition and exercise therapy is one of the main strategies in the treatment. Pilates may be preferred as one of the alternative treatment method.

This randomized controlled study was designed to compare the effects of two different treatment protocols, Group-I (Supervised Rehabilitation) and Group-II (Pilates Exercises). Patients who applied to the Istanbul Physical Therapy and Rehabilitation Training and Research Hospital, Sports Medicine outpatient clinic and were diagnosed with PFP by a specialist physician based on the patient histories, physical examinations, and diagnostic imaging. The estimated desired sample size was at least 14 participants per group. We anticipated a dropout rate of 20%. Therefore, 34 participants were required for each group (Supervised Rehabilitation n=17, Pilates Exercises n=17) of both sexes, ages ranging from 18-45 years. A computer generated randomization list was used to divide the patients into two groups (https://www.randomizer.org/). An 'Informed Consent Form' was obtained from patients by explaining the purpose of the study, the duration of the study, the treatments to be applied, and possible side effects.